Speaking of which, we noticed some great changes in Abbott Laboratories' (NYSE:ABT) returns on capital, so let's have a look. Just to clarify if you're unsure, ROCE is a metric for evaluating how ...
Many Abbott Laboratories (NYSE:ABT) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When analyzing insider transactions, it is usually more ...
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures and sells healthcare products ...
Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company To get a sense of who is truly in control of Abbott Laboratories (NYSE ...
In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other best medical device stocks to buy right now. According to a report by Mordor Intelligence ...
On January 22, Abbott Laboratories published financial results for the fourth quarter of 2024, initially receiving mixed reactions from Wall Street. However, its revenue was about $10.97 billion ...
Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Abbott Laboratories (NYSE:ABT).
Abbott Laboratories closed 2024 with an impressive 10.1% organic revenue growth, surpassing consensus estimates. This performance was particularly notable given the lower-than-expected Covid ...
The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter ...
Also Read: Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System CEO Robert Ford outlined key growth opportunities for the Diabetes Care division.
Hosted on MSN29d
Abbott Laboratories (NYSE:ABT) Q4 2024 Earnings Call TranscriptAbbott Laboratories (NYSE:ABT) Q4 2024 Earnings Call Transcript January 22, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.34 EPS, expectations were $1.34.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results